JF
KALV

Jump Financial’s KalVista Pharmaceuticals KALV Stock Holding History

Jump Financial’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90,742
Closed -$1.47M – 2151
2025
Q4 		$1.47M Buy
+90,742
New +$1.2M 0.02% 819
2024
Q2 		– Sell
-15,500
Closed -$184K – 2033
2024
Q1 		$184K Buy
+15,500
New +$207K 0.01% 1703
2023
Q4 		– Sell
-10,200
Closed -$98.2K – 2000
2023
Q3 		$98.2K Sell
10,200
-16,942
-62% -$173K ﹤0.01% 1679
2023
Q2 		$244K Buy
+27,142
New +$250K 0.01% 1415
2022
Q4 		– Sell
-12,200
Closed -$177K – 1817
2022
Q3 		$177K Sell
12,200
-10,900
-47% -$152K 0.01% 1373
2022
Q2 		$227K Buy
+23,100
New +$255K 0.01% 1219
2022
Q1 		– Sell
-26,400
Closed -$349K – 1722
2021
Q4 		$349K Sell
26,400
-4,379
-14% -$69.7K 0.02% 811
2021
Q3 		$537K Buy
+30,779
New +$624K 0.04% 454

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jump Financial's KALV Position: Q1 2026 in Review

Jump Financial sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 90,742 shares — an estimated $1.47M sold.

Jump Financial first reported a position in KALV in Q3 2021 and held it in 8 quarters. The position peaked at $1.47M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Jump Financial reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 90,742 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
  • Jump Financial first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 8 quarters.
  • Jump Financial's KalVista Pharmaceuticals position peaked at $1.47M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.